The Efficacy of Recombinant Drugs in COVID-19 Treatment

Authors: Zarei G

DOI: 10.23880/apct-16000220

Volume 8, Issue 3

Abstract

The SARS-CoV2 virus, which causes COVID-19, is a potentially fatal illness that raises serious global public health concerns. By leveraging the spike protein’s exceptional specificity, researchers have harnessed it as a valuable tool for distinguishing SARS-CoV-2. To treat and cure those struggling with COVID-19, a variety of medications, including remdesivir, dexamethasone, baricitinib, ivermectin are also employed, as well as recombinant protein drugs (Bamlanivimab, Casirivimab/Imdevimab, Tixagevimab/Cilgavimab, and Sotrovimab). The aim of this study is to look into how these kinds of drugs affect people. Overall, due to the information achieved from different results, it can be seen that each monoclonal antibody has its own effect, which can be different among different variants. In conclusion, it should be notice that it is better that antibodies target not only the spike protein but also other proteins as well. This review examined that in order to defeat the SARSCoV2 it must be better to use the combination of monoclonal antibodies like VIR-7831 which was mentioned before. Due to the information achieved by several manuscripts the combined use of both antibodies and antivirals must be considered as well.

Keywords: SARS-Cov2; COVID-19; Recombinant Drugs; Monoclonal Antibody

View PDF